NAVB - Navidea Biopharmaceuticals, Inc

NYSE American - Nasdaq Real Time Price. Currency in USD
0.4351
+0.0053 (+1.2331%)
As of 2:19PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.4298
Open0.4141
Bid0.4351 x 1100
Ask0.4400 x 400
Day's Range0.4202 - 0.4499
52 Week Range0.2900 - 0.8500
Volume105,780
Avg. Volume350,954
Market Cap70.489M
Beta-1.19
PE Ratio (TTM)0.96
EPS (TTM)0.4520
Earnings DateMar 24, 2017 - Mar 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • Business Wire24 days ago

    Navidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Event

    Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the LD Micro 10th Annual Main Event in Los Angeles, CA on December 5-7, 2017.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of NAVB earnings conference call or presentation 8-Nov-17 1:30pm GMT

    Q3 2017 Navidea Biopharmaceuticals Inc Earnings Call

  • ACCESSWIRElast month

    Navidea Biopharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Navidea Biopharmaceuticals, Inc. (NYSE: NAVB ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 ...

  • Associated Presslast month

    Navidea reports 3Q loss

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 1 cent. The biopharmaceutical posted revenue of $223,700 in the period. Its adjusted revenue was $224,000. In the final minutes ...

  • SmarterAnalyst2 months ago

    Why Shares of Navidea Biopharmaceuticals Inc (NAVB) Are Surging 25%

    It’s been a good day for shareholders of tiny-size biotech company Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB). Shares of Navidea spiked sharply Friday after the company announced the execution of a non-binding letter of intent with CerveauTechnologies sub-licensing the worldwide rights to conduct research using NAV4694, a beta-amyloid imaging agent being evaluated as an aid in the differential diagnosis of early-onset Alzheimer’s disease, as well as an exclusive license for the development and commercialization of NAV4694 in Australia, Canada, China, and Singapore. NAVB has a 1-year high of $1.16 and a 1-year low of $0.29.

  • Capital Cube2 months ago

    ETFs with exposure to Navidea Biopharmaceuticals, Inc. : October 23, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Navidea Biopharmaceuticals, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
    Capital Cube3 months ago

    Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Navidea Biopharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Navidea Biopharmaceuticals, Inc. – Immunomedics, Inc., AMAG Pharmaceuticals, Inc., Cardinal Health, Inc., International Isotopes Inc., Fonar Corporation, iCAD, Inc. and Austal Limited Sponsored ADR (IMMU-US, AMAG-US, CAH-US, INIS-US, ... Read more (Read more...)

  • Business Wire3 months ago

    Navidea Biopharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

    Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the Rodman & Renshaw 19th Annual Global Investment Conference, being held September 10-12, 2017, in New York, NY.

  • Business Wire4 months ago

    Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A with Management

    Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and through its subsidiary Macrophage Therapeutics, immunotherapeutics, announced today that it will hold an Investor Relations -focused, online Question & Answer Session with Jed Latkin, Chief Financial and Chief Operating Officer of Navidea on Tuesday, September 5 at 4:30pm Eastern Time.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of NAVB earnings conference call or presentation 9-Aug-17 12:00pm GMT

    Q2 2017 Navidea Biopharmaceuticals Inc Earnings Call

  • Associated Press4 months ago

    Navidea reports 2Q loss

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 3 cents. Losses, adjusted to account for discontinued operations, were 2 cents per share. The biopharmaceutical posted revenue ...

  • ACCESSWIRE4 months ago

    Investor Network: Navidea Biopharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB ) will be discussing their earnings results in their Q2 Earnings Call to be held August 9, 2017 at 8:00 ...

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results

    Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter of 2017.

  • Business Wire6 months ago

    Navidea Enters Exclusive License and Distribution Agreement For India with Sayre Therapeutics

    Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it has entered into an exclusive license and distribution agreement with Sayre Therapeutics for the development and commercialization of Tc 99m tilmanocept in India.

  • Business Wire6 months ago

    Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe

    Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that its European commercial partner, SpePharm AG, an affiliate of Norgine, B.V., launched LYMPHOSEEK® , originally developed by Navidea, in Denmark, the Netherlands and the UK.

  • Capital Cube6 months ago

    ETFs with exposure to Navidea Biopharmaceuticals, Inc. : June 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Business Wire6 months ago

    Navidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference

    Navidea Biopharmaceuticals, Inc. , a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 7th Annual LD Micro Invitational investor conference being held June 6-7, 2017 in Los Angeles, CA.

  • Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
    Capital Cube7 months ago

    Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Navidea Biopharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Navidea Biopharmaceuticals, Inc. – Immunomedics, Inc., AMAG Pharmaceuticals, Inc., Eli Lilly and Company, General Electric Company, Cardinal Health, Inc., International Isotopes Inc., Fonar Corporation and iCAD, Inc. (IMMU-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT

    Q1 2017 Navidea Biopharmaceuticals Inc Earnings Call